The Rising Global Burden of MASLD and Other Metabolic Diseases (2000–2021)
United European Gastroenterology Journal · 2025-09 · 13 (7) · 1141-1154
DOI: 10.1002/ueg2.70072 ↗Kurz gefasst
Fachartikel in der Zeitschrift United European Gastroenterology Journal, online erschienen am 03.07.2025. Verfasst von Pojsakorn Danpanichkul und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA. Hauptthemen laut MEDLINE: Global Burden of Disease, Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease, Metabolic Diseases. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MCIN/AEI/10.13039/501100011033, Generalitat de Catalunya through the CERCA Programme, Texas Tech University Health Sciences Center.
Abstract (Originalsprache)
Background
Metabolic diseases are a public health threat to diverse populations worldwide. This study aims to update the epidemiological trends of metabolic diseases across regions and sociodemographic stratifications using the Global Burden of Diseases Study 2021.
Methods
This study focused on metabolic dysfunction‐associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) along with obesity, hypertension, and dyslipidemia. The prevalence and disability‐adjusted life years (DALYs) with their age‐standardised prevalence rate and DALYs (ASPR and ASDALYs) and uncertainty intervals (UIs) were estimated and stratified by sex, geography, and the Sociodemographic Index (SDI). Epidemiological trends were analysed using the Joinpoint Regression method, which calculated the annual percent change (APC) and confidence intervals (CIs) of age‐standardised rates (ASRs) from 2000 to 2021.
Results
In 2021, MASLD had a prevalence of 1.27 billion people (ASPR: 15,018.07, 95% UI: 13,756.47 to 16,361.44; ASDALYs: 42.40, 95% UI: 33.60 to 53.31), while T2DM had a prevalence of 0.51 billion people (ASPR: 5885.40, 95% UI: 5467.62 to 6334.18; ASDALYs: 871.78, 95% UI: 735.05 to 1044.78) worldwide. ASPRs of MASLD and T2DM increased over the 2 decades. ASDALYs decreased over time for dyslipidemia (APC: −1.43%, 95% CI: −1.58 to −1.27%) and hypertension (APC: −1.32%, 95% CI: −1.43 to −1.21%) but increased for T2DM (APC: 1.09%, 95% CI: 1.04 to 1.14%) and obesity (APC: 0.70%, 95% CI: 0.63 to 0.78%), while it remained stable for MASLD. The global burden of metabolic diseases was generally higher in males compared to females. The highest ASDALYs for all these metabolic diseases were observed in low‐middle SDI countries.
Conclusion
The global burden of MASLD and other metabolic diseases is substantial. National and global policies must better address metabolic diseases including the MASLD public health threat.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
- Immunology Unit, Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
- MASLD Research Center, Division of Gastroenterology and Hepatology, University of California San Diego, San Diego, California, USA.
- Departamento de Gastroenterologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile.
- Observatorio Multicéntrico de Enfermedades Gastrointestinales, OMEGA, Santiago, Chile.
- Division of Gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine, Phoenix, Arizona, USA.
ORCID-Profile: Pojsakorn Danpanichkul, Mark D Muthiah, Juan Pablo Arab, Jeffrey V Lazarus, Karn Wijarnpreecha
Förderung
- MCIN/AEI/10.13039/501100011033
- Generalitat de Catalunya through the CERCA Programme
- Texas Tech University Health Sciences Center
Zitieren
APA
Danpanichkul, P., Suparan, K., Diaz, L. A., Fallon, M. B., Chen, V. L., Namsathimaphorn, K., Rakwong, K., Inkongngam, T., Kaeosri, C., Kalligeros, M., Wattanachayakul, P., Ng, C. H., Takahashi, H., Huang, D. Q., Muthiah, M. D., Arab, J. P., Kim, D., White, T. M., Noureddin, M., …, & Wijarnpreecha, K. (2025). The Rising Global Burden of MASLD and Other Metabolic Diseases (2000–2021). United European Gastroenterology Journal, 13(7), 1141-1154. https://doi.org/10.1002/ueg2.70072
Vancouver
Danpanichkul P, Suparan K, Diaz LA, Fallon MB, Chen VL, Namsathimaphorn K, et al. The Rising Global Burden of MASLD and Other Metabolic Diseases (2000–2021). United European Gastroenterology Journal. 2025;13(7):1141-1154. doi:10.1002/ueg2.70072
BibTeX
@article{Danpanichkul2025,
author = {Danpanichkul, Pojsakorn and Suparan, Kanokphong and Diaz, Luis Antonio and Fallon, Michael B and Chen, Vincent L and Namsathimaphorn, Kornnatthanai and Rakwong, Krittameth and Inkongngam, Torlap and Kaeosri, Chuthathip and Kalligeros, Markos and Wattanachayakul, Phuuwadith and Ng, Cheng Han and Takahashi, Hirokazu and Huang, Daniel Q and Muthiah, Mark D and Arab, Juan Pablo and Kim, Donghee and White, Trenton M and Noureddin, Mazen and Bugianesi, Elisabetta and Jepsen, Peter and Wong, Vincent W S and Lazarus, Jeffrey V and Wijarnpreecha, Karn},
title = {The Rising Global Burden of MASLD and Other Metabolic Diseases (2000–2021)},
journal = {United European Gastroenterology Journal},
year = {2025},
volume = {13},
number = {7},
pages = {1141--1154},
doi = {10.1002/ueg2.70072}
}
EUVIMED